ADC Therapeutics SA (ADCT)
$1.12+$0.00 (+0.02%) Today
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
https://www.adctherapeutics.comSEC filings for ADCT on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 11 | 1,628,700 | |
| Tax withholding / forfeiture | 7 | 70,348 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
25 Form 4 filings on record, the earliest from Dec 6, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mohamed Zaki - Officer | Grant or award | Common Shares | 213,900 | $0.00 | - | |
| Peter J. Graham - Officer | Grant or award | Common Shares | 221,100 | $0.00 | - | |
| Jose Carmona - Officer | Grant or award | Common Shares | 203,700 | $0.00 | - | |
| Ameet Mallik - Officer | Grant or award | Common Shares | 675,000 | $0.00 | - | |
| Robert Azelby - Director | Grant or award | Common Shares | 45,000 | $0.00 | - | |
| Robert Azelby - Director | Tax withholding / forfeiture | Common Shares | 12,600 | $3.08 | $39K | |
| Ron Squarer - Director | Grant or award | Common Shares | 45,000 | $0.00 | - | |
| Ron Squarer - Director | Tax withholding / forfeiture | Common Shares | 15,196 | $3.08 | $47K | |
| Victor Sandor - Director | Grant or award | Common Shares | 45,000 | $0.00 | - | |
| Victor Sandor - Director | Tax withholding / forfeiture | Common Shares | 12,600 | $3.08 | $39K | |
 Viviane Monges - Director | Grant or award | Common Shares | 45,000 | $0.00 | - | |
| Viviane Monges - Director | Tax withholding / forfeiture | Common Shares | 2,596 | $3.08 | $8K | |
| Peter Hug - Director | Tax withholding / forfeiture | Common Shares | 2,156 | $3.08 | $7K | |
| Peter Hug - Director | Grant or award | Common Shares | 45,000 | $0.00 | - | |
| Jean-Pierre Bizzari - Director | Grant or award | Common Shares | 45,000 | $0.00 | - | |
| Jean-Pierre Bizzari - Director | Tax withholding / forfeiture | Common Shares | 12,600 | $3.08 | $39K | |
| Timothy Coughlin - Director | Grant or award | Common Shares | 45,000 | $0.00 | - | |
| Timothy Coughlin - Director | Tax withholding / forfeiture | Common Shares | 12,600 | $3.08 | $39K | |
| Redmile Group, LLC - 10% Owner | Open-market sale | Common Stock | 196,229 | $3.75 | $736K | |
| Redmile Group, LLC - 10% Owner | Open-market sale | Common Stock | 188,407 | $3.75 | $707K | |
| Redmile Group, LLC - 10% Owner | Open-market sale | Common Stock | 169,265 | $3.80 | $643K | |
| Redmile Group, LLC - 10% Owner | Open-market sale | Common Stock | 162,517 | $3.80 | $617K | |
| Redmile Group, LLC - 10% Owner | Open-market sale | Common Stock | 2,634,506 | $3.28 | $8.64M | |
| Redmile Group, LLC - 10% Owner | Open-market sale | Common Stock | 2,529,491 | $3.28 | $8.29M | |
| Lisa Michelle Kallebo - Officer | Grant or award | Common Shares | 62,900 | $3.99 | $251K | |
| Lisa Michelle Kallebo - Officer | Tax withholding / forfeiture | Common Shares | 5,433 | $3.99 | $22K | |
| Mohamed Zaki - Officer | Grant or award | Common Shares | 285,200 | $3.99 | $1.14M | |
| Mohamed Zaki - Officer | Tax withholding / forfeiture | Common Shares | 24,603 | $3.99 | $98K | |
| Peter J. Graham - Officer | Grant or award | Common Shares | 294,800 | $3.99 | $1.18M | |
| Peter J. Graham - Officer | Tax withholding / forfeiture | Common Shares | 33,294 | $3.99 | $133K | |
| Jose Carmona - Officer | Grant or award | Common Shares | 271,600 | $3.99 | $1.08M | |
| Jose Carmona - Officer | Tax withholding / forfeiture | Common Shares | 25,880 | $3.99 | $103K | |
| Ameet Mallik - Officer | Grant or award | Common Shares | 900,000 | $3.99 | $3.59M | |
| Ameet Mallik - Officer | Tax withholding / forfeiture | Common Shares | 103,231 | $3.99 | $412K | |
| Redmile Group, LLC - 10% Owner | Open-market purchase | Pre-Funded Warrants | 3,846,153 | $3.90 | $15.00M | |
| Redmile Group, LLC - 10% Owner | Open-market purchase | Pre-Funded Warrants | 3,846,153 | $3.90 | $15.00M | |
| Redmile Group, LLC - 10% Owner | Open-market purchase | Common Shares, par value CHF 0.08 per share | 50,000 | $2.28 | $114K | |
| Redmile Group, LLC - 10% Owner | Open-market purchase | Common Shares, par value CHF 0.08 per share | 50,000 | $3.81 | $191K | |
| Redmile Group, LLC - 10% Owner | Open-market purchase | Common Shares, par value CHF 0.08 per share | 50,000 | $2.28 | $114K | |
| Redmile Group, LLC - 10% Owner | Open-market purchase | Common Shares, par value CHF 0.08 per share | 50,000 | $3.81 | $191K | |
| Mohamed Zaki - Officer | Tax withholding / forfeiture | Common Shares | 37,112 | $3.13 | $116K | |
| Ameet Mallik - Officer | Tax withholding / forfeiture | Common Shares | 238,343 | $3.13 | $746K | |
| Lisa Michelle Kallebo - Officer | Tax withholding / forfeiture | Common Shares | 6,503 | $3.13 | $20K | |
| Jose Carmona - Officer | Tax withholding / forfeiture | Common Shares | 48,108 | $3.13 | $151K | |
| Peter J. Graham - Officer | Tax withholding / forfeiture | Common Shares | 41,458 | $3.13 | $130K | |
| Redmile Group, LLC - 10% Owner | Open-market sale | Common Shares, par value CHF 0.08 per share | 25,352 | $2.07 | $52K | |
| Redmile Group, LLC - 10% Owner | Other | Common Shares, par value CHF 0.08 per share | 50,672 | $2.07 | $105K | |
| Redmile Group, LLC - 10% Owner | Other | Common Shares, par value CHF 0.08 per share | 50,672 | $2.07 | $105K | |
| Redmile Group, LLC - 10% Owner | Other | Common Shares, par value CHF 0.08 per share | 50,672 | $2.07 | $105K | |
| Redmile Group, LLC - 10% Owner | Other | Pre-Funded Warrants | 26,656 | $2.07 | $55K | |
| Redmile Group, LLC - 10% Owner | Other | Pre-Funded Warrants | 26,656 | $2.07 | $55K | |
| Redmile Group, LLC - 10% Owner | Other | Pre-Funded Warrants | 26,656 | $2.07 | $55K |
ADC Therapeutics SA (ADCT) had 11 insider filings in the last 90 days, with the most recent on 2026-07-02. The full record for ADCT runs to 25 Form 4 filings, the earliest from 2024-12-06. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ADCT were filed in the last 90 days. 6 purchases are on record for this company.
No insider sales of ADCT were filed in the last 90 days. 7 sales are on record for this company.
This page tracks ADCT Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ADCT to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
